Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.

Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well

NVAX stock seems positioned for further gains with the firm's vaccine deliveries set to begin in early 2022. The post Novavax Stock Is Poised to Climb Further appeared first on InvestorPlace.

Novavax Stock Is Poised to Climb Further

Novavax's (NVAX) Management on H.C. Wainwright 23rd Annual Global Investment Conference - Transcript

BioNTech SE

Moderna

Pfizer

Coronavirus vaccine stocks Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) were trading notably lower Monday. What Happened: A new review authored by a group of international scientists and published by the Lancet suggeststhat booster doses of the COVID-19 vaccine may not be currently needed for the general population.

Why Moderna, BioNTech, Novavax And Pfizer Are Trading Lower

NVAX stock trades at an attractive price compared with its peers as the market hasn't priced in its long-term growth potential. The post Novavax Will Enter the Covid-19 Vaccine Race With a Bang appeared first on InvestorPlace.

Novavax Will Enter the Covid-19 Vaccine Race With a Bang

This latecomer may come out ahead in one particular area in the long run.

Here's Where Novavax May Beat Moderna and Pfizer

Vertex Pharmaceuticals

The arguments for these two stocks are compelling.

2 Biotech Stocks That Are Better Buys Than Moderna

FuelCell Energy

Kroger

Dave & Buster's

Novavax, FuelCell Energy, Kroger and Dave & Buster's were our top stock trades for Monday. Let's look at the charts after a busy Friday.

4 Top Stock Trades for Monday: NVAX, FCEL, KR, PLAY

Novavax is still deeply undervalued. NVAX stock has a good chance of rising to $403.75 once its Covid 19 vaccine rolls out successfully.

Novavax Could Rise 56% Once Its Covid-19 Vaccine Is Approved

A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock.

Why Novavax Stock Is Slipping Again Today

Now is not the time to bet against NVAX stock. The technicals are strong, while Novavax has strong growth estimates for earnings and revenue.

How Novavax Stock Can Rally 30% to New Highs

The CDC had great news for participants in Novavax's clinical studies, but it wasn't very important for Novavax itself.

What Should Novavax Investors Make of the CDC's Latest Guidance?

Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.

Why Novavax Stock Slipped Today

The combined vaccine for Covid-19 and influenza as well as the traditional/trusted vaccine manufacturing process provides a strong competitive edge to Novavax.

Novavax: Entering The Race Soon With A Bang

Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.

Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

Novavax used a conventional technology to develop a vaccine, which has slowed development and approval. But there is still time for it to make some big sales.

Novavax Stock Is Best Covid Vaccine Name To Speculate On

Novavax Inc (NASDAQ: NVAX) has enrolled the first participants in a Phase 1/2 study to test its combined flu and COVID-19 vaccine. The trial combines Novavax's recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine).

Novavax Starts COVID-19, Flu Combination Vaccine Trial

Kansas City Southern

HyreCar

Philip Morris

QUALCOMM

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Kansas City Southern among others.

Kansas City Southern Ranked Among Today's Trending Stocks Amid Market Movers Like Covid, Tapering Talk, And More

GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax' seasonal influenza and COVID-19 vaccines.

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

How high can the share price of pharmaceutical company Novavax go? That's the question investors should be asking themselves as they evaluate the Gaithersburg, Maryland-based company.

Novavax Stock Is a Buy Ahead of Potential EU and U.S. Approvals

The biotech's coronavirus-related revenue could be about to soar.

Why Novavax Stock Surged Today

A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly.

NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today

Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda Pharmaceutical Company Limited (NYSE: TAK) announced Monday that Japan's Health Ministry has agreed to purchase 150 million doses of Novavax's vaccine candidate manufactured by it in Japan.

Novavax Shares Surge On Vaccine Supply Deal With Japan

GAITHERSBURG, Md., Sept. 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi's 16th Annual BioPharma Virtual Conference 2021 investor conference.

Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

While NVAX stock works its way towards all-time highs, traders should prepare for a breakout as Novavax makes headway in vaccine development. The post Government Support Puts Novavax on a Faster Path to Success appeared first on InvestorPlace.

News for Novavax Stock (NVAX)